Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 as a Vaccine Induces Synergistic Antitumor Activities

Jian-mei Hou; Ji-yan Liu; Li Yang; Xia Zhao; Ling Tian; Zhen-yu Ding; Yan-jun Wen; Ting Niu; Fei Xiao; Yan-yan Lou; Guang-hong Tan; Hong-xin Deng; Jiong Li; Jin-liang Yang; Yong-qiu Mao; Bing Kan; Yang Wu; Qiu Li; Yu-quan Wei

doi:10.1159/000087303

Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 as a Vaccine Induces Synergistic Antitumor Activities

Oncology ◽

10.1159/000087303 ◽

2005 ◽

Vol 69 (1) ◽

pp. 81-87 ◽

Cited By ~ 22

Author(s):

Jian-mei Hou ◽

Ji-yan Liu ◽

Li Yang ◽

Xia Zhao ◽

Ling Tian ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Low Dose ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

Endothelial Growth Factor

Download Full-text

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2007.03.023 ◽

2007 ◽

Vol 25 (4) ◽

pp. 359-360

Author(s):

Gregory Metzger

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Potent Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

Endothelial Growth Factor

Download Full-text

KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties

Cancer Research ◽

10.1158/0008-5472.can-05-4290 ◽

2006 ◽

Vol 66 (18) ◽

pp. 9134-9142 ◽

Cited By ~ 124

Author(s):

Kazuhide Nakamura ◽

Eri Taguchi ◽

Toru Miura ◽

Atsushi Yamamoto ◽

Kazumi Takahashi ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Potent Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

Endothelial Growth Factor

Download Full-text

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-08-0652 ◽

2008 ◽

Vol 14 (22) ◽

pp. 7272-7283 ◽

Cited By ~ 389

Author(s):

Dana D. Hu-Lowe ◽

Helen Y. Zou ◽

Maren L. Grazzini ◽

Max E. Hallin ◽

Grant R. Wickman ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Growth Factor Receptor ◽

Selective Inhibitor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

Endothelial Growth Factor

Download Full-text

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

Onkologische Welt ◽

10.1055/s-0038-1631032 ◽

2012 ◽

Vol 03 (02) ◽

pp. 93-92

Author(s):

Alexander Kretzschmar

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Medulläres Schilddrüsenkarzinom ◽

Epidermal Growth ◽

Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Download Full-text

Expression des „Epidermal Growth-Factor Receptor“ (EGFR) und des „Vascular Endothelial Growth Factor“ (VEGF) bei Lymphangioleiomyomatose (LAM)

Pneumologie ◽

10.1055/s-2006-934022 ◽

2006 ◽

Vol 60 (S 1) ◽

Author(s):

H Watz ◽

K Engels ◽

M Amthor ◽

D Kirsten ◽

H Magnussen

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1163678.625451 ◽

2009 ◽

Author(s):

David Bates

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.12828054 ◽

2011 ◽

Author(s):

Asma Nusrat

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.13740054 ◽

2011 ◽

Author(s):

Richard L Stevens

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697854.793153053 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Neoadjuvant Treatment ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Receptor Inhibitor

Download Full-text

Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells

Journal of Chinese Integrative Medicine ◽

10.3736/jcim20101105 ◽

2010 ◽

Vol 8 (11) ◽

pp. 1029-1035

Author(s):

YR Zhang

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Gastric Carcinoma ◽

Low Dose ◽

Vascular Endothelial ◽

Cxc Chemokine Receptor 4 ◽

Protein Expressions ◽

Cxc Chemokine ◽

Chemokine Receptor 4 ◽

Endothelial Growth Factor

Download Full-text